- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GSK
Recent news which mentions GSK
From Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
From Benzinga
GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead
November 23, 2021
From Benzinga
Will Investors Benefit From Johnson & Johnson's Breakup?
November 23, 2021
From Motley Fool
2 Cheap Pharma Stocks That Pay A Tidy Dividend
November 22, 2021
From Motley Fool
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
November 18, 2021
From Benzinga
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
From Benzinga
Europe is the only region where COVID-19 deaths rose in the latest week, and U.S. to greatly expand vaccine manufacturing
November 17, 2021
From MarketWatch
US Government Agrees To Purchase GSK-Vir Biotech's COVID-19 Antibody Doses Worth $1B
November 17, 2021
From Benzinga
The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment
November 17, 2021
From Benzinga
This Treasury dealer says the market has it entirely wrong on the Fed and interest rates. Here’s why.
November 17, 2021
From MarketWatch
From MarketWatch
Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows
November 17, 2021
From Motley Fool
GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19
November 12, 2021
From Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
November 11, 2021
From Motley Fool
GlaxoSmithKline Spotlights Encouraging Data For Anemia Drug
November 08, 2021
Tickers
GSK
From Benzinga
Why Vir Biotechnology Stock Is Sliding Today
November 05, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
From Benzinga
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
From Benzinga
From Motley Fool
Exxon Mobil as COP26 play? Here’s why Morgan Stanley says some of the dirtiest companies will benefit from decarbonization.
November 01, 2021
From MarketWatch
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
These 3 Unique Stocks Have Undeniable Long-Term Upside
October 29, 2021
From Motley Fool
Shell stock tumbles after disappointing results as activist investor Third Point calls for a breakup
October 28, 2021
From MarketWatch
From Benzinga
GlaxoSmithKline plc (GSK) Q2 2021 Earnings Call Transcript
October 27, 2021
Tickers
GSK
From Motley Fool
GlaxoSmithKline Drops Research On Otilimab In COVID-19
October 27, 2021
From Benzinga
Glaxo Reports Double-Digit Growth In Q3 Pharma, Vaccine Sales, Updates FY21 Guidance
October 27, 2021
Tickers
GSK
From Benzinga
Should Biogen Investors Be Preparing for the Worst?
October 27, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.